Alexander Jamnišek is a Senior Patent Attorney at the Biopharmaceuticals business unit of Sandoz, a Novartis Division, headquartered in Holzkirchen (greater Munich area), Germany. Alexander has extensive experience in the realm of biosimilars and the field of corresponding intellectual property rights. Alexander has particular expertise and a record of achievement in freedom-to-operate, legal validity and infringement analyses and advising development teams on related design-around strategies, clear-the-way activities such as oppositions, patent revocation actions and US IPRs, pre-litigation and litigation activities as well as patent prosecution matters around the globe. In addition, Alexander has supported several due diligences and cooperation projects from an IP perspective. Before joining Sandoz, Alexander worked in private practice with a patent law firm in Munich specialized in life and natural sciences.

Alexander is a Slovenian national and studied biology at the Ludwig-Maximilians-Universität (LMU) in Munich, Germany, pursued his doctoral studies in the field of molecular biology and genetics at the LMU and Max Planck Institute for Terrestrial Microbiology in Marburg, Germany, where he was awarded the doctoral degree (Dr. rer. nat.) from the Philipps-Universität Marburg.

Sandoz (www.sandoz.com) is the pioneer and a global leader in biosimilars. Sandoz invests in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics. Sandoz was the first pharmaceutical company to receive approval of a biosimilar in Europe, Japan and the United States. Sandoz biosimilars have been used in clinical practice for over 10 years, are available in over 90 countries and have over 500 million patient-days of experience. In addition to eight marketed biosimilars across immunology, oncology and endocrinology, Sandoz also has a leading biosimilars pipeline with several molecules in various stages of development.
(www.sandoz.com)